Multiple Sclerosis Treatment in the COVID-19 Era: A Risk-Benefit Approach.
Neurology International（2022）
Key words
multiple sclerosis,COVID-19,SARS-CoV-2,anti-CD20,fingolimod,ocrelizumab,S1P-modulators,DMD,MS therapy-related risks,vaccination
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined